

Yong Fan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1919/publications.pdf>

Version: 2024-02-01

22
papers

558
citations

686830

13
h-index

676716

22
g-index

24
all docs

24
docs citations

24
times ranked

621
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1048-1054.	0.5	126
2	Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 175-191.	1.6	53
3	Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. <i>Frontiers in Oncology</i> , 2021, 11, 633032.	1.3	53
4	Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 443-445.	0.5	40
5	Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies. <i>Autoimmunity Reviews</i> , 2020, 19, 102687.	2.5	35
6	Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases. <i>Chest</i> , 2022, 161, 1675-1686.	0.4	27
7	Advances on immune-related adverse events associated with immune checkpoint inhibitors. <i>Frontiers of Medicine</i> , 2021, 15, 33-42.	1.5	24
8	Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials. <i>European Journal of Internal Medicine</i> , 2021, 87, 20-28.	1.0	24
9	Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. <i>Drugs of Today</i> , 2022, 58, 23-32.	0.7	23
10	Systemic lupus erythematosus: year in review 2019. <i>Chinese Medical Journal</i> , 2020, 133, 2189-2196.	0.9	20
11	Mortality in patients with primary Sjögren's syndrome: a systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 4029-4038.	0.9	18
12	Identification of exosome miRNAs in bronchial epithelial cells after PM2.5 chronic exposure. <i>Ecotoxicology and Environmental Safety</i> , 2021, 215, 112127.	2.9	17
13	Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials. <i>Clinical Rheumatology</i> , 2019, 38, 2765-2776.	1.0	15
14	Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2020, 59, 3400-3407.	0.9	15
15	Phenotype and function of macrophage polarization in monocrotaline-induced pulmonary arterial hypertension rat model. <i>Physiological Research</i> , 2021, 70, 213-226.	0.4	15
16	Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 123.	1.6	14
17	Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells. <i>International Journal of Medical Sciences</i> , 2017, 14, 820-828.	1.1	10
18	Determinants and protective associations of the lupus low disease activity state in a prospective Chinese cohort. <i>Clinical Rheumatology</i> , 2022, 41, 357-366.	1.0	10

#	ARTICLE	IF	CITATIONS
19	Towards a Better Implementation of Treat-to-Target Strategy in Rheumatoid Arthritis: A Comparison of Two Real-World Cohorts. <i>Rheumatology and Therapy</i> , 2022, 9, 907-917.	1.1	7
20	Cysteine-rich protein 61 as a novel biomarker in systemic lupus erythematosus-associated pulmonary arterial hypertension. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 623-632.	0.4	5
21	Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study. <i>Lupus Science and Medicine</i> , 2022, 9, e000553.	1.1	4
22	Predicting lupus low disease activity state and remission in SLE: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1083-1089.	1.3	3